Patient and office support for MYCAPSSA® (octreotide)

Patient Support

Patient Support

The Chiasma Access and Patient Support Program (CAPS) offers a dedicated, personalized patient support system to help appropriate patients with acromegaly get started on MYCAPSSA and guide them throughout their treatment.

Your CAPS Patient Care Specialist will provide your office one-on-one assistance to ensure seamless reimbursement access, benefits investigation, and specialty pharmacy interactions for your patients. They’ll also provide patients with ongoing education and tools to help them every step of the way.

CAPS Patient Care Specialist Services:

A simple enrollment form helps start the process so a dedicated CAPS Patient Care Specialist working with your office can alleviate hurdles and ensure patient access to MYCAPSSA. The Patient Care Specialist will facilitate:

Benefits Investigation to evaluate insurance coverage for each patient and assist with authorization forms

Speciality Pharmacy Interactions to coordinate set-up and delivery of MYCAPSSA for the patient

Financial Assistance for out-of-pocket expenses or for individuals without insurance

In addition to the services above, the Patient Care Specialists will provide ongoing support for your patients once they have started on MYCAPSSA, guiding them through their new treatment routine and ensuring that they have the support they need.

Learn more about the CAPS program and how we can help get your patients started today. Download additional details about the CAPS program and fill out the enrollment form for appropriate patients with acromegaly that you recommend transitioning to MYCAPSSA. We look forward to facilitating the process and assisting your practice and patients in their journey to start and manage their acromegaly treatment with MYCAPSSA.

Sign up now

Learn more about how MYCAPSSA is changing acromegaly treatment.

   

*Required Field

 

By clicking ‘Submit,’ I agree to receive communications from Chiasma, Inc., and I understand that my information will be used in accordance with the Chiasma, Inc. Privacy Policy.

READ MORE  

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE
MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

CONTRAINDICATIONS
Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS
MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

ADVERSE REACTIONS
The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.

DRUG INTERACTIONS
The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women to use an alternative non-hormonal method of contraception or a back-up method when MYCAPSSA is used with combined oral contraceptives.

Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.

PREGNANCY
Advise premenopausal females of the potential for an unintended pregnancy.

To report SUSPECTED ADVERSE REACTIONS, contact the product information department at 1-844-312-2462 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

READ MORE  

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE
MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

CONTRAINDICATIONS
Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS
MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

ADVERSE REACTIONS
The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.

DRUG INTERACTIONS
The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women to use an alternative non-hormonal method of contraception or a back-up method when MYCAPSSA is used with combined oral contraceptives.

Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.

PREGNANCY
Advise premenopausal females of the potential for an unintended pregnancy.

To report SUSPECTED ADVERSE REACTIONS, contact the product information department at 1-844-312-2462 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

REFERENCES

1. Colao A, et al. Nat Rev Dis Primers 2019;5(1):20. 2. MYCAPSSA. Prescribing information. Chiasma, Inc.;2020. 3. Samson SL, et al. J Clin Endocrinol Metab. 2020;105(10):dgaa526. 4. Melmed S, et al. J Clin Endocrinol Metab. 2015;100(4):1699-1708. 5. Geer EB, et al. Pituitary. 2020. https://doi.org/10.1007/s11102-019-01013-2 6. Strasburger CJ, et al. Eur J Endocrinol. 2016;174(3):355-362. 7. Karsdal MA, et al. Br J Clin Pharmacol. 2015;79(5):720-732. 8. Data on file. Chiasma, Inc.